Gammella Elena, Diaz Victor, Recalcati Stefania, Buratti Paolo, Samaja Michele, Dey Soumyadeep, Noguchi Constance Tom, Gassmann Max, Cairo Gaetano
Department of Biomedical Sciences for Health, University of Milano, Milan, Italy;
Institute of Veterinary Physiology, Vetsuisse Faculty, and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland;
Am J Physiol Regul Integr Comp Physiol. 2015 Feb 15;308(4):R330-5. doi: 10.1152/ajpregu.00410.2014. Epub 2014 Dec 17.
Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythropoietic cells. In the search for erythroid regulators of hepcidin, many candidates have been proposed, including Epo itself. We aimed to test whether direct interaction between Epo and the liver is required to regulate hepcidin. We found that prolonged administration of high doses of Epo in mice leads to great inhibition of liver hepcidin mRNA levels, and concomitant induction of the hepcidin inhibitor erythroferrone (ERFE). Epo treatment also resulted in liver iron mobilization, mediated by increased ferroportin activity and accompanied by reduced ferritin levels and increased TfR1 expression. The same inhibitory effect was observed in mice that do not express the homodimeric Epo receptor (EpoR) in liver cells because EpoR expression is restricted to erythroid cells. Similarly, liver signaling pathways involved in hepcidin regulation were not influenced by the presence or absence of hepatic EpoR. Moreover, Epo analogs, possibly interacting with the postulated heterodimeric β common EpoR, did not affect hepcidin expression. These findings were supported by the lack of inhibition on hepcidin found in hepatoma cells exposed to various concentrations of Epo for different periods of times. Our results demonstrate that hepcidin suppression does not require the direct binding of Epo to its liver receptors and rather suggest that the role of Epo is to stimulate the synthesis of the erythroid regulator ERFE in erythroblasts, which ultimately downregulates hepcidin.
在红细胞生成加速的情况下,促红细胞生成素(Epo)水平升高与铁调素合成受抑制有关,这一反应最终会增加铁的可利用性,以满足红细胞生成细胞对铁需求的增加。在寻找铁调素的红细胞调节因子时,人们提出了许多候选因子,包括Epo本身。我们旨在测试Epo与肝脏之间的直接相互作用是否是调节铁调素所必需的。我们发现,在小鼠中长期给予高剂量Epo会导致肝脏铁调素mRNA水平受到极大抑制,并伴随铁调素抑制剂红系铁调素(ERFE)的诱导。Epo治疗还导致肝脏铁动员,这是由铁转运蛋白活性增加介导的,同时伴有铁蛋白水平降低和转铁蛋白受体1(TfR1)表达增加。在肝细胞中不表达同型二聚体Epo受体(EpoR)的小鼠中也观察到了相同的抑制作用,因为EpoR的表达仅限于红细胞系细胞。同样,参与铁调素调节的肝脏信号通路不受肝脏EpoR存在与否的影响。此外,可能与假定的异型二聚体β共同EpoR相互作用的Epo类似物也不影响铁调素的表达。在不同时间段暴露于不同浓度Epo的肝癌细胞中未发现对铁调素的抑制作用,这支持了上述发现。我们的结果表明,铁调素的抑制并不需要Epo直接与其肝脏受体结合,而是提示Epo的作用是刺激成红细胞中红细胞调节因子ERFE的合成,最终下调铁调素。